In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets

[1]  V. Torri,et al.  Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. , 2022, European journal of cancer.

[2]  A. Cusmai,et al.  Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential , 2022, Expert opinion on investigational drugs.

[3]  G. Brandi,et al.  Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects , 2021, Expert opinion on investigational drugs.

[4]  A. Ricci,et al.  Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond , 2021, Expert opinion on investigational drugs.

[5]  R. Sitarz,et al.  Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review , 2021, Cancers.

[6]  B. Berman,et al.  A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes , 2021, Nature Communications.

[7]  Yan Li,et al.  miR-301b-3p Regulates Breast Cancer Cell Proliferation, Migration, and Invasion by Targeting NR3C2 , 2021, Journal of oncology.

[8]  Juan Fan,et al.  CLIP4 Shows Putative Tumor Suppressor Characteristics in Breast Cancer: An Integrated Analysis , 2021, Frontiers in Molecular Biosciences.

[9]  Xuning Wang,et al.  Genome-Wide Analysis of Methylation-Driven Genes and Identification of an Eight-Gene Panel for Prognosis Prediction in Breast Cancer , 2020, Frontiers in Genetics.

[10]  Lu Lu,et al.  Pex3 is involved in the genetic regulation of Nr3c2 expression in the amygdala of mice , 2020, Psychiatry Research.

[11]  Maolan Li,et al.  Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer , 2019, J. Comput. Biol..

[12]  C. Plass,et al.  Random forest-based modelling to detect biomarkers for prostate cancer progression , 2019, Clinical Epigenetics.

[13]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[14]  J. Bussink,et al.  Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer. , 2019, Biomarkers in medicine.

[15]  Haoyi Jin,et al.  Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer , 2018, Cancer Cell International.

[16]  X. Shu,et al.  Gene expression in triple-negative breast cancer in relation to survival , 2018, Breast Cancer Research and Treatment.

[17]  Ling Wang,et al.  Prognostic genes of breast cancer revealed by gene co-expression network analysis. , 2017, Oncology letters.

[18]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[19]  D. Nomura,et al.  GSTP1 Is a Driver of Triple-Negative Breast Cancer Cell Metabolism and Pathogenicity. , 2016, Cell chemical biology.

[20]  M. Arock,et al.  The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment , 2015, International journal of cancer.

[21]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[22]  H. Zhang,et al.  The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration. , 2015, Biochimica et biophysica acta.

[23]  C. García-echeverría,et al.  Antibody-drug conjugates—a new wave of cancer drugs. , 2014, Bioorganic & medicinal chemistry letters.

[24]  M. Klüppel,et al.  Chondroitin Sulfate-E Is a Negative Regulator of a Pro-Tumorigenic Wnt/Beta-Catenin-Collagen 1 Axis in Breast Cancer Cells , 2014, PloS one.

[25]  Chuan He,et al.  HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis , 2013, Proceedings of the National Academy of Sciences.

[26]  A. Ho,et al.  Radiation therapy in the management of breast cancer. , 2013, The Surgical clinics of North America.

[27]  M. Esteller,et al.  BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer , 2012, Epigenetics.

[28]  Peter T. Simpson,et al.  Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression , 2012, Breast Cancer Research and Treatment.

[29]  G. Luisetto,et al.  Endocrine therapy of breast cancer. , 2011, Current medicinal chemistry.

[30]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[31]  A. Toland,et al.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.

[32]  M. Brito,et al.  eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development. , 2009, Oncology reports.

[33]  Juanita Lopez,et al.  The context and potential of epigenetics in oncology , 2009, British Journal of Cancer.

[34]  S. Chen‐Kiang,et al.  CDK2 Phosphorylation of Smad2 Disrupts TGF-β Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells1 , 2009, The Journal of Immunology.

[35]  Timothy Hunter,et al.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer , 2009, Breast Cancer Research and Treatment.

[36]  G. Parmigiani,et al.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.

[37]  Craig D. Shriver,et al.  A gene expression signature that defines breast cancer metastases , 2008, Clinical & Experimental Metastasis.

[38]  Kjetil Søreide,et al.  Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[39]  Wei Zhang,et al.  Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients , 2007, Breast Cancer Research and Treatment.

[40]  Hao Zhang,et al.  Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS , 2006, Nucleic acids research.

[41]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[42]  Renato Paro,et al.  Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. , 2004, Annual review of genetics.

[43]  S. Vokes,et al.  A role for the RNA-binding protein, hermes, in the regulation of heart development. , 2002, Developmental biology.

[44]  T. Matsumoto,et al.  A unique human gene that spans over 230 kb in the human chromosome 8p11-12 and codes multiple family proteins sharing RNA-binding motifs. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Simard,et al.  Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. , 1990, Endocrinology.